Targets for Growth Factor Signalling and Methods of Therapy
OwnerTristan Croll, Gary Keith Shooter +4inventors
InventorsTristan Croll, Gary Keith Shooter, Jesse Ray Peet, Simone Rizzl, Derek Robert Von Lonkhuyzen, Zee Upton
Life of this patent
Estimating the term…
Abstract
Methods of screening or designing therapeutic agents effective for the treatment of a transglutaminase-associated disease, disorder and/or condition are provided which include determining whether a candidate agent can modulate an interaction between a transglutaminase and an insulin-like growth factor and/or a member of the IGF family of receptors. Also provided are pharmaceutical compositions and methods of treatment using said pharmaceutical compositions.
Claims40
A method of screening, designing, engineering or otherwise producing a therapeutic agent effective for the treatment of a transglutaminase-associated disorder, disease and/or condition, said method including the step of determining whether a candidate agent can modulate an interaction between
- (i) a TG and an IGF;
- and/or
- (ii) a TG and a member of the IGF receptor family.
5-7. (canceled)
(canceled)
(canceled)
(canceled)
A pharmaceutical composition for treating a transglutaminase-associated disorder, disease and/or condition comprising a therapeutic agent selected from the group consisting of:
- (i) an isolated transglutaminase (TG), or a fragment thereof;
- (ii) an isolated TG substrate, or a fragment thereof;
- (iii) an isolated insulin-like growth factor (IGF) amino acid sequence, or an analogue thereof, together with an isolated polypeptide, or a fragment thereof, that binds to or interacts with an extracellular matrix;
- (iv) a modulator of an interaction between a TG and an IGF;
- and
- (v) a modulator of an interaction between a TG and a member of IGF receptor family,
- and a pharmaceutically-acceptable diluent, carrier or excipient.
31-39. (canceled)
42-45. (canceled)
A method of treating a transglutaminase-associated disorder, disease and/or condition, said method including the step of modulating an interaction between
- (i) a TG and an IGF;
- and/or
- (ii) a TG and a member of IGF receptor family,
- to thereby treat a transglutaminase-associated disorder, disease and/or condition.
(canceled)
(canceled)
52-57. (canceled)
An isolated protein complex comprising:
- (i) a TG, or fragment thereof and an IGF, or fragment thereof;
- (ii) a TG, or fragment thereof and a member of IGF receptor family, or fragment thereof.
Dependencies are inferred from the claim text.